Why the study?
Does AT(1)- and AT(2)-receptor activation affect EGF-induced DNA synthesis and ERK2 phosphorylation in prostate cancer cell lines?
Does AT(1)- and AT(2)-receptor activation affect EGF-induced DNA synthesis and ERK2 phosphorylation in prostate cancer cell lines?
Functional AT2 receptors are present in prostate cancer cell lines and can inhibit growth factor signaling, suggesting a potential mechanism for renin-angiotensin system involvement in prostate cancer.
AT2 receptor effects on prostate cancer cell signaling warrant no clinical action; leaves open any role for renin-angiotensin modulation in human disease.
BACKGROUND: There is clear evidence of a tissue-based renin-angiotensin system in the prostate and studies to date suggest that AT(1)-receptor blocking drugs inhibit the growth of some prostate cancer cell lines and delay the development of prostate cancer. The present studies examine the action of Ang II in two prostate cancer cell lines and report the presence of functional AT(2)-receptors that regulate the actions of growth factors. METHODS: Immunohistochemistry was used to identify the presence of Ang II and QPCR techniques to examine AT(1)- and AT(2)-receptor mRNA expression in androgen-dependent (LNCaP) and independent (PC3) cell lines. The effects of AT(1)- and AT(2)-receptor activation upon EGF-induced DNA synthesis and ERK2 phosphorylation in these cells were also examined. RESULTS: Functional AT(2)-receptors together with Ang II were identified in both cell lines and stimulation of these receptors inhibited EGF-induced DNA synthesis and ERK2 phosphorylation. AT(1)-receptors, although present in both cell lines, were only functional in LNCaP cells where activation stimulated DNA synthesis. CONCLUSIONS: Functional AT(2)-receptors are present and have the capacity to inhibit EGF-induced prostate cancer cell growth in LNCaP and fast growing androgen-independent PC3 cell lines, whereas functional AT(1)-receptors are found only in LNCaP cells where their activation stimulates DNA synthesis.
No takes yet. Share an insight, caveat, or question.
Chow et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: